FDA Outlines Rules for Telling Clinicians About Unapproved Uses of Drugs, Devices
The FDA has released revised draft guidance on communicating with healthcare professionals (HCPs) about unapproved uses of approved drugs and devices. Once it’s finalized, the document will reflect FDA’s stance on how companies can communicate scientific information to clinicians regarding unapproved uses of products already on the market. Comments are open through December 24. “In […]